Neurocrine Biosciences Inc (NBIX)
103.50
+0.16 (+0.15%)
USD |
NASDAQ |
Sep 23, 16:00
103.50
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 9.899B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 8.89% |
| Valuation | |
| PE Ratio | 940.91 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.758 |
| Price to Book Value | 6.954 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1187 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 46.39% |
News
Headline
Wire
Time (ET)
Yahoo
09/21 08:19
Yahoo
09/20 16:16
MT Newswires
09/19 12:23
PR Newswire
09/19 08:30
Yahoo
09/16 08:07
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/01/2022* | -- | Results | Q3 2022 | -- | 1.11 | -- | |
| 11/01/2022* | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | 0.84 | 0.89 | -5.69% | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | 0.30 | 0.59 | -49.25% | |
| 05/04/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/11/2022 | -- | Results | Q4 2021 | 0.04 | 0.88 | -95.48% | |
| 02/11/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. |
| URL | https://www.neurocrine.com |
| Investor Relations URL | https://neurocrine.gcs-web.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Nov. 01, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 29, 1995 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | -- |
| Yield to Sector | -- |
| Yield to Industry | -- |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | Dec. 29, 1995 |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 23, 2022.
Fundamentals
| Revenue (TTM) | 1.297B |
| Total Expenses (TTM) | 1.130B |
| Net Income (TTM) | 12.20M |
| Total Assets (Quarterly) | 2.006B |
| Total Liabilities (Quarterly) | 582.30M |
| Shareholders Equity (Quarterly) | 1.423B |
| Cash from Operations (TTM) | 163.60M |
| Cash from Investing (TTM) | -102.70M |
| Cash from Financing (TTM) | -261.00M |
Ratings
Profile
Edit
| Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. |
| URL | https://www.neurocrine.com |
| Investor Relations URL | https://neurocrine.gcs-web.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Nov. 01, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 29, 1995 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| FBT | 48.15M USD | 3.81% |
| CMIDX | 34.00M USD | 2.58% |
| ATHGX | 85.51M USD | 1.80% |
| BASAX | 33.88M USD | 1.70% |
| JFNSX | 63.86M USD | 1.55% |
| JGMCX | 105.70M USD | 1.42% |
| XBI | 73.29M USD | 1.09% |
| IJK | 67.31M USD | 1.06% |
| IBB | 75.15M USD | 1.00% |
| VISGX | 150.36M USD | 0.52% |
| VBK | 150.36M USD | 0.52% |
| IJH | 288.55M USD | 0.50% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NBIX Tweets |